Skip to main content
. 2022 Feb;33(2):342–356. doi: 10.1681/ASN.2021040439

Figure 2.

Figure 2.

Decreased kidney renalase expression in the cisplatin CKD mouse model. (A) Schematic representation of experimental design for mouse model of CKD. (B) Change in kidney RNLS mRNA levels during the course of CKD development measured by quantitative PCR (n=5, ****P<0.0001). (C) Change in kidney RNLS protein expression during CKD development measured by Western blot (n=3). (D) Quantification of immunoblot (values are the mean±SEM of three mice at each time point, **P<0.01). CP, cisplatin.